Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind international multicenter study of AP301 for hyperphosphatemia in maintenance dialysis patients with chronic kidney disease
CTR20252745Phase 3Active
- Sponsor
- Likang Life Sciences
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of AP301 in hyperphosphatemia, sponsored by Likang Life Sciences. Started Nov 2025; status: active.
02
Drugs
AP301
03
Conditions
hyperphosphatemia
Beyond the preview
Go deeper on CTR20252745.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252745.